Medically reviewed by Casey Gallagher, MD Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with ...

Discover expert-relief solutions for managing atopic dermatitis, from breakthrough treatments to daily habits that prevent ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Learn about different types of eczema, symptoms, treatment options, and how to differentiate from other skin conditions.

The Mean Girls star appeared in a Vogue Beauty Secrets video released March 18, which showed the 39-year-old actress opening up about her "unfiltered eczema routine." "You might be thinking ...

In a Vogue Beauty Secrets video released March 18, the Mamma Mia! star, 39, talked fans through her "unfiltered eczema routine," and she was immediately praised online for starting the clip with a ...

Living with eczema can lead to mental health challenges such as anxiety and depression. Managing your eczema symptoms, working with a mental health professional, and maintaining healthy lifestyle ...

Looking Past Eylea and into their Pipeline Regeneron’s other major revenue driver is Dupixent, their blockbuster treatment for asthma, eczema, and COPD, which has patent protection until October ...

Dupixent is an eczema treatment whose rights Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares with Sanofi. Eylea, which Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) comarkets with Bayer ...

At week 24, 42.3% of patients in the higher dose group achieved ≥75% reduction from baseline in Eczema Area and Severity Index score (EASI-75), a 29.5% difference vs. placebo, and 36.3% vs.

However, several Wall Street analysts compared the results to Sanofi SNY/Regeneron’s REGN blockbuster immunology drug Dupixent, which is also considered the standard of care in AD indication.

The study met its primary endpoint, but analysts compared the results unfavorably to the data on Dupixent. Adjusted for placebo, 19.1% of people on rocatinlimab had 75% improvement in eczema area ...